The Effect of Bushen Jiedu Tongluo Decoction in the treatment of active rheumatoid arthritis: a randomized, double-blind, controlled clinical study

INTERVENTION: experimental group:MTX 15mg qw po+Bushen Jiedu Tongluo Decoction Granule One dose a day, two times a day;control group:MTX 15mg qw po+placebo Granule One dose a day, two times a day; CONDITION: rheumatoid arthritis PRIMARY OUTCOME: VAS test;DAS28;Musculoskeletal ultrasound (synovitis);Musculoskeletal ultrasound (synovitis of tendon sheath);Musculoskeletal ultrasound (bone erosion);Erythrocyte sedimentation rate;C‐reactive protein; SECONDARY OUTCOME: Joint swelling count;Joint tenderness count;TCM syndrome curative effect score;HAQ Disability Index, HAQ‐DI;TNF‐a;MMP‐9;VEGF;iNOS;CX3CL1; INCLUSION CRITERIA: 1. According to the diagnostic criteria of RA, it is in accordance with the diagnostic criteria of RA in active stage, in accordance with the diagnostic criteria of traditional Chinese medicine; 2. Patients aged 18‐80 years old; 3. The dosage of corticosteroids was stable for at least 30 days before entering the trial, and remained unchanged in the following treatment. Patients receiving other DMARDs had to discontinue other DMARDs for more than 30 days; 4. At least 30 days before entering the trial, no NSAIDs were taken; 5. Sign the informed consent to enter the clinical study.